- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Resubmission to request a Section 100 (Efficient Funding of Chemotherapy Program) Authority Required (STREAMLINED) listing for the first-line treatment of recurrent or metastatic Squamous cell carcinoma of the head and neck (SCCHN).
- Meeting Date: March 2022
- Public Summary Document (PSD) March 2022 PBAC Meeting - (PDF 1.3MB)
- Public Summary Document (PSD) March 2022 PBAC Meeting - (Word 541KB)
Pembrolizumab – March 2022
Pembrolizumab (SCCHN): Solution concentrate for I.V. infusion 100 mg in 4 mL; Keytruda®
Last updated
30 May 2025